Zota Health Care Ltd
NSE:ZOTA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its 3-Year Average (157.8), the stock would be worth ₹62.11 (95% downside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 3 276.4 | ₹1 289.3 |
0%
|
| 3-Year Average | 157.8 | ₹62.11 |
-95%
|
| 5-Year Average | 136.5 | ₹53.73 |
-96%
|
| Industry Average | 21.2 | ₹8.33 |
-99%
|
| Country Average | 17.7 | ₹6.95 |
-99%
|
Forward EV/EBITDA
Today’s price vs future ebitda
| Today's Enterprise Value | EBITDA | Forward EV/EBITDA | ||
|---|---|---|---|---|
|
₹39.3B
|
/ |
Jan 2026
₹13.9m
|
= |
|
|
₹39.3B
|
/ |
Mar 2026
₹-329.5m
|
= |
|
|
₹39.3B
|
/ |
Mar 2027
₹544.7m
|
= |
|
|
₹39.3B
|
/ |
Mar 2028
₹2B
|
= |
|
Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| IN |
|
Zota Health Care Ltd
NSE:ZOTA
|
44.5B INR | 3 276.4 | -54.4 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
835.2B USD | 27.4 | 40.5 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.8B USD | 16.7 | 26 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 11.9 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.4B GBP | 15.6 | 28 | |
| CH |
|
Novartis AG
SIX:NOVN
|
223.1B CHF | 12.1 | 19.5 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
276.9B USD | 9.5 | 15.2 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 386.8 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 8.4 | 11.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
153.5B USD | 7.6 | 19.8 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.2B USD | 7.2 | 16.8 |
Market Distribution
| Min | 0.4 |
| 30th Percentile | 11.9 |
| Median | 17.7 |
| 70th Percentile | 27.8 |
| Max | 47 834.4 |
Other Multiples
Zota Health Care Ltd
Glance View
Zota Health Care Ltd. engages in the manufacture, sale and export of pharmaceutical products. The company is headquartered in Surat, Gujarat. The company went IPO on 2017-05-10. The firm offers a portfolio consisting of a range of pharmaceutical, nutraceutical, as well as ayurvedic products in India and abroad. Its domestic products include Acarbose 25/50 mg, Aceclofenac 100 mg + Paracetamol 325 mg, Aceclofenac 100 mg , Aceclofenac 200 mg SR, Albendazole 400 mg + Ivermectin 6 mg, Amilsupride 50/100/200 mg, Amitriptyline HCL 10/25 mg, and others. Its imternational products include Artemether 20/80 MG + Lumifentine 120/480 mg, Atenolol 50/100 mg, Atorvastatin 10 mg + Fenofibrate 160 mg Tab, Atorvastatin 10/20/40 mg Tab, Betahistine 16 mg Tab, Bromhexine 8 mg, Calcium 500 mg + Vit D3 250 IU, Carbamazepine 200 mg, Cetrizine 10 mg, Chlorpheniramine Maleate 4 mg, Cimetidine 200/400 mg, Citicoline 500 mg, Clopidogrel 75 mg, Clozapine 100 mg, Desloratidine 5 mg, Domperidone 10 mg DT, Escitalopram 10 mg, Finasteride 5mg, and others.
